ArticleWorld journal of surgical oncology2025
Prognostic significance of the CALLY index for cancer risk and survival: evidence from NHANES 2001-2018.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Advanced glycation end products and the CALLY index reflect inflammatory burden in familial Mediterranean fever.Scientific reports · 2026Article
- Prognostic Value of C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index for Survival in Nivolumab-Treated Metastatic Renal Cell Carcinoma.Medicina (Kaunas, Lithuania) · 2026Article
- Physical activity and cancer survival: the role of peripheral blood immune and inflammatory markers in reducing mortality-a retrospective cohort study based on NHANES 1999-2018.Translational cancer research · 2026Article
- The Impact of the CALLY Index on All-Cause Mortality in Patients With Depression: A Longitudinal Analysis Using NHANES Data.Health science reports · 2026Article
- Integrated nutritional-inflammatory and frailty-based model for mortality risk stratification following hip fracture surgery: a multicentre cohort study.Aging clinical and experimental research · 2026Article
- Editorial: Empowering cancer care through immunonutrition.Frontiers in nutrition · 2026Article
- Prognostic value of the C-reactive protein-albumin-lymphocyte index versus traditional inflammatory markers after radical resection of colorectal cancer: a retrospective cohort study.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe C-reactive protein-albumin-lymphocyte (CALLY) index is an immune-nutritional biomarker associated with cancer prognosis. Its relevance to cancer incidence and long-term survival in the general population has not been well established.
methodsWe analyzed NHANES 2001-2018 data from 36,904 participants, including 3,218 cancer patients. Logistic regression assessed cancer risk, and Cox proportional hazards models evaluated all-cause, cancer-specific, and cardiovascular mortality among cancer survivors. Restricted cubic splines (RCS) examined nonlinear associations, and subgroup analyses were stratified by age and sex.
resultsCancer patients showed lower CALLY index values. Compared with the lowest quartile, the highest quartile was associated with a reduced risk of cancer (OR = 0.77, 95% CI = 0.67-0.90, P < 0.001). RCS identified a nonlinear association with cancer incidence (P-nonlinearity = 0.003), with a threshold at 9.402 (log-transformed). Among survivors, higher CALLY index values were significantly associated with reduced all-cause (HR = 0.39), cancer-cause mortality (HR = 0.36), and cardiovascular mortality (HR = 0.32), all P < 0.001. These associations remained consistent across subgroups.
conclusionsThe CALLY index is significantly associated with cancer risk and mortality. As a simple and robust biomarker reflecting immune-nutritional status, it may be associated with cancer risk and could provide useful information for prognostic assessment. Although causal inferences cannot be drawn due to the cross-sectional design of NHANES.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.